Results 51 to 60 of about 17,802 (177)
Non-traumatic Acute Epidural Hematoma in Multiple Sclerosis Treated With Fingolimod
Frontiers in Neurology, 2019 Fingolimod acts as a functional antagonist of the sphingosine-1-phosphate receptor and is widely used for relapsing-remitting multiple sclerosis (MS).
Ryoko Fukai +6 more
doaj +1 more source
Brain Sciences, 2022 Multiple sclerosis (MS) patients receiving natalizumab and who are at risk of developing progressive multifocal leukoencephalopathy (PML) often switch to other high-efficacy disease-modifying therapies including fingolimod as a risk mitigation strategy ...
Helmut Butzkueven +10 more
doaj +1 more source
Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis
British Journal of Clinical Pharmacology, EarlyView.Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley +1 more source
Clinical effectiveness of fingolimod treatment.
, 2022 Clinical effectiveness of fingolimod treatment.
Dániel Sandi (6252581) +15 more
core +1 more source
WONOEP appraisal: Biomarkers and treatment strategies beyond the synapse
Epilepsia, EarlyView.Abstract Epilepsy is a heterogeneous neurological disorder affecting more than 70 million people worldwide, posing significant challenges for clinicians due to its complex etiology, diverse manifestations, variable treatment responses, and the inability to predict seizures or disease onset reliably.
Mirte Scheper +11 more
wiley +1 more source
The multiple hit model of infantile and epileptic spasms: The 2025 update
Epilepsia Open, EarlyView.Abstract Objective Infantile and epileptic spasms syndrome (IESS) is a developmental and epileptic encephalopathy manifesting with epileptic spasms and poor neurodevelopmental outcomes. There is an urgent need for the development of more effective and tolerated therapies.
Aristea S. Galanopoulou +6 more
wiley +1 more source
, 2011 ZusammenfassungProzesse der Signaltransduktion (Kommunikation von extra- nach intrazellulär) sind an einer Vielzahl physiologischer und pathologischer Prozesse beteiligt.
M. Ocker, B. Tackenberg, H. Strik
core +1 more source
Journal of Neuroinflammation, 2022 Background The increasing number of treatments that are now available to manage patients with multiple sclerosis (MS) highlights the need to develop biomarkers that can be used within the framework of individualized medicine.
Celia Camacho-Toledano +13 more
doaj +1 more source
Antidepressant activity of fingolimod in mice [PDF]
, 2015 Recent findings indicate that fingolimod, the first oral drug approved for the treatment of multiple sclerosis (MS), acts as a direct inhibitor of histone deacetylases (HDACs) and enhances the production of brain-derived neurotrophic factor (BDNF) in the
NICOLETTI, Ferdinando +26 more
core +2 more sources
Effect of fingolimod on platelet count among multiple sclerosis patients
International Journal of Preventive Medicine, 2015 Background: While many studies have previously focused on fingolimod′s effect on immune cells, the effect it has on circulating and local central nervous system platelets (Plts) has not yet been investigated.
Mehrdad Farrokhi +7 more
doaj +1 more source